ABBV Abbvie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Company profile

Richard Gonzalez
Fiscal year end
AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...
IRS number

ABBV stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


2 Nov 21
2 Dec 21
31 Dec 21
Quarter (USD)
Sep 21 Jun 21 Mar 21 Dec 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Abbvie earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Nov 21 Austin Roxanne S Common Stock, $0.01 par value Sell Dispose S No No 117.23 20,000 2.34M 49,284
2 Nov 21 Austin Roxanne S Common Stock, $0.01 par value Sell Dispose S No No 115.23 6,844 788.63K 69,284
2 Nov 21 Austin Roxanne S Common Stock, $0.01 par value Sell Dispose S No No 116.11 25,000 2.9M 76,128
2 Nov 21 Austin Roxanne S Common Stock, $0.01 par value Sell Dispose S No No 117.1 20,000 2.34M 101,128
30 Sep 21 Edward J Rapp Stock Equivalent Units Common Stock Grant Acquire A No No 107.87 326 35.17K 20,941
30 Sep 21 Liddy Edward M Stock Equivalent Units Common Stock Grant Acquire A No No 107.87 266 28.69K 27,506
30 Sep 21 Alpern Robert J Stock Equivalent Units Common Stock Grant Acquire A No No 107.87 66 7.12K 8,068
7 Sep 21 Henry O Gosebruch Common Stock, $0.01 par value Gift Acquire G Yes No 0 30,000 0 78,500
7 Sep 21 Henry O Gosebruch Common Stock, $0.01 par value Gift Dispose G No No 0 30,000 0 18,711

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

64.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2472 2506 -1.4%
Opened positions 118 153 -22.9%
Closed positions 152 92 +65.2%
Increased positions 1241 1198 +3.6%
Reduced positions 808 844 -4.3%
13F shares
Current Prev Q Change
Total value 123.67B 129.55B -4.5%
Total shares 1.15B 1.15B -0.4%
Total puts 18.44M 18.38M +0.3%
Total calls 18.81M 18.27M +2.9%
Total put/call ratio 1.0 1.0 -2.5%
Largest owners
Shares Value Change
Vanguard 145.53M $15.7B +0.6%
BLK Blackrock 126.84M $13.68B +3.5%
STT State Street 76.76M $8.28B +1.0%
JPM JPMorgan Chase & Co. 43.89M $4.73B +25.5%
Geode Capital Management 27.76M $2.99B +1.9%
TROW T. Rowe Price 26.21M $2.83B -9.6%
NTRS Northern Trust 22.82M $2.46B +0.7%
FMR 21.62M $2.33B -39.0%
BK Bank Of New York Mellon 21.09M $2.28B +0.5%
BAC Bank Of America 20.12M $2.17B +6.4%
Largest transactions
Shares Bought/sold Change
FMR 21.62M -13.84M -39.0%
JPM JPMorgan Chase & Co. 43.89M +8.93M +25.5%
BRK.A Berkshire Hathaway 14.4M -6.13M -29.9%
BLK Blackrock 126.84M +4.25M +3.5%
Orbis Allan Gray 3.01M -3.63M -54.7%
GS Goldman Sachs 9.88M +3.03M +44.2%
AMP Ameriprise Financial 10.46M +2.84M +37.3%
TROW T. Rowe Price 26.21M -2.79M -9.6%
Assenagon Asset Management 3.45M +2.43M +239.8%
Winslow Capital Management 0 -2.38M EXIT

Financial report summary

  • Public health outbreaks, epidemics or pandemics, such as the coronavirus (COVID-19), have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition.
  • The expiration or loss of patent protection and licenses may adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's major products could lose patent protection earlier than expected, which could adversely affect AbbVie's future revenues and operating earnings.
  • A third party's intellectual property may prevent AbbVie from selling its products or have a material adverse effect on AbbVie's future profitability and financial condition.
  • Any significant event that adversely affects Humira revenues could have a material and negative impact on AbbVie's results of operations and cash flows.
  • AbbVie's research and development efforts may not succeed in developing and marketing commercially successful products and technologies, which may cause its revenues and profitability to decline.
  • A portion of AbbVie's near-term pharmaceutical pipeline relies on collaborations with third parties, which may adversely affect the development and sale of its products.
  • Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.
  • AbbVie's biologic products are subject to competition from biosimilars.
  • New products and technological advances by AbbVie's competitors may negatively affect AbbVie's results of operations.
  • The manufacture of many of AbbVie's products is a highly exacting and complex process, and if AbbVie or one of its suppliers encounters problems manufacturing AbbVie's products, AbbVie's business could suffer.
  • AbbVie uses a number of products in its pharmaceutical and biologic manufacturing processes that are sourced from single suppliers, and an interruption in the supply of those products could adversely affect AbbVie's business and results of operations.
  • Certain aspects of AbbVie’s operations are highly dependent upon third party service providers.
  • Significant safety or efficacy issues could arise for AbbVie's products, which could have a material adverse effect on AbbVie's revenues and financial condition.
  • AbbVie is subject to product liability claims and other lawsuits that may adversely affect its business and results of operations.
  • AbbVie is subject to cost-containment efforts and pricing pressures that could cause a reduction in future revenues and operating earnings, and changes in the terms of rebate and chargeback programs, which are common in the pharmaceuticals industry, could have a material adverse effect on AbbVie's operations.
  • AbbVie is subject to numerous governmental regulations, and it can be costly to comply with these regulations and to develop compliant products and processes.
  • Laws and regulations affecting government benefit programs could impose new obligations on AbbVie, require it to change its business practices, and restrict its operations in the future.
  • The international nature of AbbVie's business subjects it to additional business risks that may cause its revenue and profitability to decline.
  • If AbbVie does not effectively and profitably commercialize its products, AbbVie's revenues and financial condition could be adversely affected.
  • AbbVie may acquire other businesses, license rights to technologies or products, form alliances, or dispose of assets, which could cause it to incur significant expenses and could negatively affect profitability.
  • AbbVie is dependent on wholesale distributors for distribution of its products in the United States and, accordingly, its results of operations could be adversely affected if they encounter financial difficulties.
  • AbbVie has debt obligations that could adversely affect its business and its ability to meet its obligations.
  • AbbVie may need additional financing in the future to meet its capital needs or to make opportunistic acquisitions, and such financing may not be available on favorable terms, if at all.
  • AbbVie depends on information technology and a failure of those systems could have a material adverse effect on AbbVie's business.
  • In connection with the acquisition of Allergan, AbbVie’s balances of intangible assets, including developed product rights and goodwill acquired, have increased significantly. Such balances are subject to impairment testing and may result in impairment charges, which will adversely affect AbbVie’s results of operations and financial condition.
  • Failure to attract and retain highly qualified personnel could affect AbbVie’s ability to successfully develop and commercialize products.
  • Other factors can have a material adverse effect on AbbVie's profitability and financial condition.
  • AbbVie cannot guarantee the timing, amount, or payment of dividends on its common stock.
  • An AbbVie stockholder's percentage of ownership in AbbVie may be diluted in the future.
  • Certain provisions in AbbVie's amended and restated certificate of incorporation and amended and restated by-laws, and of Delaware law, may prevent or delay an acquisition of AbbVie, which could decrease the trading price of AbbVie's common stock.
Management Discussion
  • AbbVie's strategy has focused on delivering strong financial results, maximizing the benefits of the Allergan acquisition, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company's financial performance in 2020 included delivering worldwide net revenues of $45.8 billion, operating earnings of $11.4 billion, diluted earnings per share of $2.72 and cash flows from operations of $17.6 billion. Worldwide net revenues increased by 38% on a reported basis and on a constant currency basis, which included $10.3 billion of contributed revenues from the Allergan acquisition, growth in the immunology portfolio from Skyrizi, Rinvoq and the continued strength of Humira in the U.S. as well as revenue growth from Imbruvica and Venclexta.
Content analysis
H.S. freshman Avg
New words: adjunctive, antirheumatic, axial, baseline, Boxed, death, deleveraging, demonstrated, demonstrating, diabetic, flat, gene, HCl, holding, intention, intolerant, JAK, MDD, methotrexate, mix, municipal, numerical, Parkinson, personal, pilocarpine, pivotal, post, Qulipta, redemption, refinanced, refinancing, REGENXBIO, retinal, retinopathy, score, statistical, statistically, stay, stayed, subset, TNF, tofacitinib, tolerate, unchanged, vii, voluntarily, Vuity, week, workplace
Removed: determine, experimental, myeloid, outbreak, stage, tablet, unfavorably


Inhibitors of ROR gamma
30 Nov 21
The present disclosure relates to salts and crystalline forms of a compound having the formula (I): Also described are processes for the production of the salts and crystalline forms described herein.
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
30 Nov 21
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Methods of Treating Crohn's Disease and Ulcerative Colitis
25 Nov 21
The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor.
Use of Inhibitors of Brutons Tyrosine Kinase (BTK)
25 Nov 21
Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor.
Modulators of the Integrated Stress Pathway
25 Nov 21
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.